亚洲以外NK/T细胞慢性活动性EB病毒病患者复发风险高
该回顾性国际队列纳入亚洲以外57例慢性活动性EB病毒病(CAEBV)患者,治疗方式多样但多数最终接受异基因造血干细胞移植(HSCT)。接受HSCT者生存优于未接受者(55% vs 25%,P < .01),但HSCT后死亡者中75%死于疾病复发。
要点
- 亚洲以外CAEBV患者接受HSCT者生存优于未移植者(55% vs 25%,P < .01)。
- HSCT后死亡患者中75%归因于疾病复发。
- 淋巴瘤发生与死亡率升高呈趋势(56% vs 35%,P = .1)。
核心结论
- 亚洲以外CAEBV患者即使接受HSCT仍有较高死亡率,且HSCT后死亡绝大多数由疾病复发导致。
研究设计与样本
- 回顾性国际队列研究,纳入亚洲以外57例CAEBV患者。
主要发现
- 接受HSCT者生存率55%,未接受HSCT者25%(P < .01)。
- HSCT后死亡患者中75%死于复发疾病。
- 淋巴瘤发生与死亡率升高呈趋势(56% vs 35%,P = .1)。
- 死亡率 largely 不受年龄、种族、细胞类型受累或疾病并发症影响。
临床怎么用
- 对晚期CAEBV需优化疾病控制策略并尽早转诊行HSCT。
- HSCT后应密切随访,积极管理血EBV DNA水平升高。
局限性
- 回顾性研究设计,样本量57例,治疗方式差异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is characterized by high levels of EBV predominantly in T and/or natural killer cells with lymphoproliferation, organ failure due to infiltration of tissues with virus-infected cells, hemophagocytic lymphohistiocytosis, and/or lymphoma. The disease is more common in Asia than in the United States and Europe. Although allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only curative therapy for CAEBV, its efficacy and the best treatment modality to reduce disease severity prior to HSCT is unknown. Here, we retrospectively assessed an international cohort of 57 patients outside of Asia. Treatment of the disease varied widely, although most patients ultimately proceeded to HSCT. Though patients undergoing HSCT had better survival than those who did not (55% vs 25%, P < .01), there was still a high rate of death in both groups. Mortality was largely not affected by age, ethnicity, cell-type involvement, or disease complications, but development of lymphoma showed a trend with increased mortality (56% vs 35%, P = .1). The overwhelming majority (75%) of patients who died after HSCT succumbed to relapsed disease. CAEBV remains challenging to treat when advanced disease is present. Outcomes would likely improve with better disease control strategies, earlier referral for HSCT, and close follow-up after HSCT including aggressive management of rising EBV DNA levels in the blood.
引用
- Dávila Saldaña BJ, John T, Bonifant C, et al. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022. PMID: 34670275. doi:10.1182/bloodadvances.2021005291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。